<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="26744">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01916915</url>
  </required_header>
  <id_info>
    <org_study_id>09/06</org_study_id>
    <nct_id>NCT01916915</nct_id>
  </id_info>
  <brief_title>Usage of Tramadol With Levobupivacaine for Pain Treatment After Cesarean Section</brief_title>
  <official_title>The Effect of Addition of Tramadol to Levobupivacaine in Continuous Wound Infusion for Postoperative Pain Treatment in Cesarean Section</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ufuk University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ufuk University</source>
  <oversight_info>
    <authority>Turkey: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients experience considerable amount of pain after cesarean section. The aim of this
      study is to investigate the effect of tramadol (an opioid pain killer) added to
      levobupivacaine (a local anesthetic) in continuous wound infusion (which is done by placing
      a catheter in the incision) after cesarean sections.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">September 2013</completion_date>
  <primary_completion_date type="Anticipated">August 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>lowering of pain as measured by visual analogue scores</measure>
    <time_frame>forty eight hours after the operation</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>total additional analgesic consumption</measure>
    <time_frame>forty eight hours after the operation</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Postoperative Pain Following Cesarean Section</condition>
  <arm_group>
    <arm_group_label>Tramadol 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 mg/kg tramadol + 0.25% levobupivacaine 4 ml/h infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tramadol 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2mg/kg tramadol + 0.25% levobupivacaine 4 ml/h infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Levobupivacaine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.25% levobupivacaine 4ml/h infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tramadol infusion via wound catheter</intervention_name>
    <arm_group_label>Tramadol 1</arm_group_label>
    <arm_group_label>Tramadol 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levobupivacaine</intervention_name>
    <arm_group_label>Tramadol 1</arm_group_label>
    <arm_group_label>Tramadol 2</arm_group_label>
    <arm_group_label>Levobupivacaine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Planned cesarean section

          -  American Society of Anesthesiologists Class I-II

        Exclusion Criteria:

          -  Patients refusing to enroll in the study

          -  Serious coagulopathy

          -  Serious systemic disease

          -  Story of allergy to drugs being used in the study

          -  Morbid obesity (Body mass index &gt; 30)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Perihan Ekmekçi, Associate Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ufuk University Dr Rıdvan Ege Hospital Department of Anesthesiology and Reanimation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Perihan Ekmekçi</last_name>
    <phone>903122044000</phone>
    <email>erdogduperi@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ufuk University Dr Rıdvan Ege Hospital</name>
      <address>
        <city>Ankara</city>
        <zip>06520</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Perihan Ekmekçi, MD</last_name>
      <phone>903122044000</phone>
      <email>erdogduperi@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Gamze S Çağlar, Associate Professor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 5, 2013</lastchanged_date>
  <firstreceived_date>August 1, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ufuk University</investigator_affiliation>
    <investigator_full_name>Perihan Ekmekçi</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tramadol</mesh_term>
    <mesh_term>Levobupivacaine</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
